{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Suramin_Sodium",
  "nciThesaurus": {
    "casRegistry": "129-46-4",
    "chebiId": "",
    "chemicalFormula": "C51H34N6O23S6.6Na",
    "definition": "A sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity.  Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration.  This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis.",
    "fdaUniiCode": "89521262IH",
    "identifier": "C1848",
    "preferredName": "Suramin Sodium",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C1971"
    ],
    "synonyms": [
      "309 F",
      "8,8'-(Carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino))bis-1,3,5-naphthalenetrisulfonic Acid Hexasodium Salt",
      "Antrypol",
      "Bayer 205",
      "Belganyl",
      "CI-1003",
      "Fourneau 309",
      "Germanin",
      "Metaret",
      "Moranyl",
      "Naganin",
      "Naganinum",
      "Naganol",
      "Naphuride",
      "SURAMIN SODIUM",
      "Sodium Suramin",
      "Sodium suramin",
      "Suramin Hexasodium",
      "Suramin Sodium",
      "Suramin sodium"
    ]
  }
}